Taken together, our results further indicated that EGCG can affect ERα expression in ERα-negative breast cancer cells through influencing epigenetic mechanisms and this effect was strengthened in the presence of TSA, a deacetylation inhibitor. This evidence concerns the gene ESR1 and breast carcinoma.